Background: Chromogranin A (CgA) and other peptides from the chromogranin-secretogranin family have been recently studied as potential biomarkers of various neurodegenerative diseases, including Parkinson's disease (PD).
Methods: We measured CgA in the cerebrospinal fluid (CSF) of 119 PD patients, 18 multiple system atrophy (MSA) patients, and 31 age-matched controls. We also correlated the values with disease duration and levodopa dose equivalent.
Results: In the PD patients, CSF CgA tended to be lower than the control group (median 124.5 vs. 185.2 µg/L; = 0.057); however, the results did not reach statistical significance. CSF CgA levels in MSA were significantly lower compared to the control group (median 104.4 vs. 185.2; = 0.014). There was no significant difference in CSF CgA between PD and MSA patients ( = 0.372). There was no association between CSF CgA and disease duration or levodopa dose equivalent in PD or in MSA.
Conclusions: We observed a tendency toward lower CSF CgA levels in both PD and MSA compared to the control group; however, the difference reached statistical significance only in MSA. Based on these results, CgA may have potential as a biomarker in PD and MSA, but further studies on larger numbers of patients are needed to draw conclusions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912438 | PMC |
| http://dx.doi.org/10.3390/brainsci11020141 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel plasma protein biomarkers: A time-dependent predictive model for Alzheimer's disease.
Arch Gerontol Geriatr
February 2025
School of Nursing, Nanjing Medical University, Nanjing, Jiangsu 211166, PR China. Electronic address:
Background: The accurate prediction of Alzheimer's disease (AD) is crucial for the efficient management of its progression. The objective of this research was to construct a new risk predictive model utilizing novel plasma protein biomarkers for predicting AD incidence in the future and analyze their potential biological correlation with AD incidence.
Methods: A cohort of 440 participants aged 60 years and older from the Alzheimer's Disease Neuroimaging Initiative (ADNI) longitudinal cohort was utilized.
Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABAR Antibodies.
Neurol Neuroimmunol Neuroinflamm
May 2024
From the French Reference Center on Paraneoplastic Neurological Syndrome and Autoimmune Encephalitis (F.L., V.R., G.P., M.V., A.-L.P., M.B., B.J., J.H.), Hospices Civils de Lyon; Institut MeLiS INSERM U1314/CNRS UMR 5284 (F.L., V.R., G.P., M.V., A.-L.P., M.B., B.J., J.H.), Université Claude Bernard Lyon 1; Department of Neurology (F.L.), University Hospital of La Réunion, Saint-Pierre (La Réunion), France; Department of Neurology (J.K., M.H.V.C.-H., M.A.D.B., J.M.V., M.J.T.), Erasmus Medical Center, Rotterdam, The Netherlands; Stanford Center for Sleep Sciences and Medicine (S.M.-C., V.P.S., E.M.), Stanford University, Palo Alto, CA; Clinical Neurology (A.V.), Department of Neurosciences, Azienda Sanitaria Universitaria Friuli Centrale (ASU FC); Department of Medicine (DAME) (A.V.), University of Udine Medical School, Italy; Department of Immunology (D.G.), Hôpital Lyon Sud, Hospices Civils de Lyon, France; Department of Immunology (M.S.), Laboratory Medical Immunology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Neurology (L.T., L.H.), University Hospital of Nancy; Department of Clinical Neurosciences (J.A., C.M.), University Hospital of Bordeaux, Bordeaux, France; Department of Neuro-Oncology (D.P.), Pitié Salpêtrière Hospital, AP-HP, Paris; Department of Neurology (L.K.), University Hospital of Strasbourg; Department of Neurology (V.B.), Côte d'Azur University, Nice; Department of Neurology (J.-C.G.A.), University Hospital of Saint-Etienne; Stroke Center Neurology Division (A.W.), Hopital Foch, Suresnes; University Grenoble Alpes (P.K.), Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences; Neurological Intensive Care Unit (S.D.), Pitié-Salpêtrière Hospital, AP-HP, Paris; Department of Neurology (G.A.), Hôpitaux Civils de Colmar; Department of Public Health (N.T., M.N.), Hospices Civils de Lyon; and Department of Medicine (A.M.), Centre Leon Berard, UNICANCER, Lyon, France.
Background And Objectives: While patients with paraneoplastic autoimmune encephalitis (AE) with gamma-aminobutyric-acid B receptor antibodies (GABAR-AE) have poor functional outcomes and high mortality, the prognosis of nonparaneoplastic cases has not been well studied.
Methods: Patients with GABAR-AE from the French and the Dutch Paraneoplastic Neurologic Syndromes Reference Centers databases were retrospectively included and their data collected; the neurologic outcomes of paraneoplastic and nonparaneoplastic cases were compared. Immunoglobulin G (IgG) isotyping and human leukocyte antigen (HLA) genotyping were performed in patients with available samples.
Diagnostic value of CSF chromogranin A to discriminate between Alzheimer's disease and dementia with Lewy bodies.
Neuropathol Appl Neurobiol
February 2024
ICube Laboratory UMR 7357 and FMTS (Fédération de Médecine Translationnelle de Strasbourg), IMIS team, University of Strasbourg and CNRS, Strasbourg, France.
Article Synopsis
- Chromogranin A (CgA) levels in cerebrospinal fluid (CSF) were found to be higher in Alzheimer's disease (AD) and patients with both AD and Lewy Body Dementia (DLB), compared to those with DLB alone, indicating distinct roles in neurodegenerative diseases.* -
- Analysis indicated significant correlations between CgA concentrations and tau proteins, suggesting that CgA may be linked to tau-related neurodegeneration, regardless of the specific disease.* -
- Overall, the study highlights the potential of using CgA levels to differentiate between AD and DLB, with a notable area under the ROC curve of 0.791, indicating good discriminatory capacity.*
The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis.
Front Neurol
February 2023
Department of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Article Synopsis
- Optic neuritis (ON) often signals the onset of multiple sclerosis (MS) and other related disorders, with high-dose corticosteroids recommended for treatment but not adequately studied regarding timing and patient antibodies.
- The Acute Optic Neuritis Network (ACON) aims to investigate how the timing of corticosteroid treatment affects visual outcomes 6 months post-ON onset by enrolling patients who present within 30 days of initial symptoms.
- The study will collect extensive data on various ON subtypes and factors like visual acuity, imaging results, and patient-reported outcomes from 28 hospitals globally, targeting a recruitment of 200 patients across different ON classifications.
CSL324, a granulocyte colony-stimulating factor receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa.
Br J Dermatol
April 2023
CSL Innovation, Melbourne, VIC 3052, Australia.
Background: Neutrophils have been shown to contribute to the pathophysiology of hidradenitis suppurativa (HS), a chronic, painful and debilitating inflammatory skin disease, yet their exact role remains to be fully defined. Granulocyte colony-stimulating factor (G-CSF), a major regulator of neutrophil development and survival, can be blocked by the novel, fully human anti-G-CSF receptor (G-CSFR) monoclonal antibody CSL324.
Objectives: We investigated the activation and migration of neutrophils in HS and the impact of blocking G-CSFR with CSL324.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!